Sector: Health Care
Director information for IMMUNOME INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Carol Schafer | Director | 62 | ["more than 25 years of experience in healthcare investment banking and equity capital markets","Managing Partner at Hyphen Advisors, LLC","Vice Chair, Equity Capital Markets at Wells Fargo Securities","Vice President of Finance and Business Development at Lexicon Pharmaceuticals, Inc.","Managing Director of Equity Capital Markets at J.P. Morgan","board member of Insmed Incorporated, Kura Oncology, Inc.","former board member of Five Prime Therapeutics, Repare Therapeutics Inc., and Idera Pharmaceuticals, Inc.","M.B.A. from New York University’s Stern School of Business","B.A. from Boston College"] | ["Audit (Chair)","Nominating and Corporate Governance"] | 2026 |
| Clay Siegall, Ph.D. | President, Chief Executive Officer and Chairman of the Board | 65 | ["Ph.D. in Genetics from George Washington University","B.S. in Zoology from the University of Maryland","Experience in drug research, development and commercialization","Leadership skills for life sciences companies","Scientific understanding and corporate vision","Experience serving on boards of directors of publicly-traded biopharmaceutical companies"] | [] | 2026 |
| Isaac Barchas, J.D. | Director | 58 | ["Lead independent director of the Board since October 2023","Member of the board of directors of Research Bridge Partners since January 2017","President and Chief Executive Officer of Research Bridge Partners from January 2017 until January 2024","Director of the Austin Technology Incubator from 2006 to 2016","Worked at McKinsey & Company from 1996 to 2006","Board member of Courage Therapeutics, Inc. since May 2025","Board member of Tetricus Labs from October 2022 until January 2026","B.A. from Stanford University","M.A. and J.D. from the University of Chicago","Extensive investment and business experience in life sciences and biotechnology sectors"] | ["Compensation","Nominating and Corporate Governance"] | 2026 |
| James Boylan | Chief Executive Officer | 59 | ["significant venture capital experience","public company board experience","extensive experience in the biotechnology and life sciences industry"] | ["Compensation (Chair)","Nominating and Corporate Governance"] | 2026 |
| Jean-Jacques Bienaimé | Director | 72 | ["M.B.A. from the Wharton School at the University of Pennsylvania","degree in economics from the Ecole Superieure de Commerce de Paris","extensive business and operating experience in the life sciences and biotechnology sectors","experience managing and serving on boards of public biotechnology companies"] | ["Audit","Compensation"] | 2026 |
| Philip Wagenheim | Director | 55 | ["extensive experience as a venture capital investor in the life sciences industry","financial expertise"] | [] | 2026 |
| SANDRA SWAIN, M.D. | Director | 72 | ["Associate Dean for Research Development at Georgetown University Medical Center since July 2016","Professor of Medicine at Georgetown University Medical Center since June 2007","Vice President of Genetic Medicine at MedStar Health since January 2018","Extensive research and clinical trial experience, particularly in oncology","Experience on the board of directors of Seagen, Inc."] | ["Audit Committee"] | 2026 |
